Sanofi buys Provention Bio for $2.9 billion

French pharmaceutical group Sanofi said on Monday that it would buy Provention Bio, Inc., a US-based biopharmaceutical company focused on autoimmune diseases, for $25 per share. bonds in cash, in an equity deal of $2.9 billion. This agreement will allow Sanofi to add TZIELD to its portfolio. approved in the US last year is the first disease-modifying treatment to slow Type 1 Stage 3 (T1D) diabetes. Provention announced late last year an agreement with Sanofi to jointly promote treatment in the United States.


News7F: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button